SCHEMBL1174136

SCHEMBL1174136

CC1(C)CN(Cc2ccccc2)CC(C=O)=C1Cl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
SIGMAR1 Q99720 2/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
DRD2 P14416 2/20 0.38
DRD4 P21917 2/20 0.38
DRD3 P35462 2/20 0.38
MC4R P32245 1/20 0.38
CYP2D6 P10635 2/20 0.38
ELANE P08246 1/20 0.37
POLB P06746 1/20 0.37
ACHE P22303 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12883369 0.86 GAA (0.48) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL3006044 0.69 ACHE (0.53) GAAMEN1KMT2ALMNAALDH1A1
SCHEMBL3006047 0.69 ACHE (0.53) GAAMEN1KMT2ALMNAALDH1A1
SCHEMBL13264469 0.68 ERN1 (0.47) MEN1KMT2ASIGMAR1DRD2DRD4
SCHEMBL2913069 0.68 GAA (0.47) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL10990414 0.67 GAA (0.67) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL653269 0.67 GAA (0.57) GAAMEN1KMT2ATSHRSIGMAR1
SCHEMBL1171606 0.67 SIGMAR1 (0.53) SIGMAR1LMNAALDH1A1DRD2DRD4
SCHEMBL17485212 0.67 SLC6A5 (0.46) MEN1KMT2ASIGMAR1DRD2DRD4
SCHEMBL29598556 0.66 GAA (0.61) GAAMEN1KMT2ATSHRSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108570059-B Compound with PRMT5 inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2022-02-08 CN disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed
US-8624040-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 US disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 WO disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329836-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 GAA 46/4885MEN1 3742/4885KMT2A 87/4885
US-20110046157-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 GAA 46/4885MEN1 3742/4885KMT2A 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.